PeptideLabs Logo
PeptideLabs
All profiles

Lixisenatide

Peptide · Metabolism & GLP-1

Influences post-meal glucose mainly through insulin, glucagon and gastric-emptying signals.

Approved for specific uses
LibraryNo account · this device only

Also known as: GLP-1 · Adlyxin · Lyxumia

Use at a glance

Lixisenatide

Influences post-meal glucose mainly through insulin, glucagon and gastric-emptying signals.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Medicine instructions · named product only

Product or source: Lixisenatide · SOLIQUA 100/33

What amount?
15 U (pen) = 5 µg lixisenatide
How often?
once per day
What time of day?
meal-related
In what setting?
entry

mg and µg: substance amount · ml: liquid volume. Depending on the product, U can mean a device scale or units of activity. IU and USP U are activity units, not ml or pen clicks. These measures are not interchangeable.

How is it used?
The named medicines are ready-made injectable solutions. Their instructions and device are product-specific.
Does it need mixing?
No. The named ready-made solutions are not mixed with water. A research powder is a different product.
View preparationCheck sources
Overview of all entries

  • Lixisenatide · entry

    Medicine instructions · named product only · SOLIQUA 100/33

    15 U (pen) = 5 µg lixisenatide · once per day · meal-related

  • Lixisenatide · entry

    Medicine instructions · named product only · SOLIQUA 100/33

    30 U (pen) = 10 µg lixisenatide · once per day · meal-related

  • Lixisenatide · upper reports

    Medicine instructions · named product only · SOLIQUA 100/33

    60 U (pen) = 20 µg lixisenatide · once per day · meal-related

mg and µg: substance amount · ml: liquid volume. Depending on the product, U can mean a device scale or units of activity. IU and USP U are activity units, not ml or pen clicks. These measures are not interchangeable.

More factsPeptide · Metabolism & GLP-1
Classification
Peptide · Metabolism & GLP-1
Research focus
Influences post-meal glucose mainly through insulin, glucagon and gastric-emptying signals.
Evidence
Established
Status
Approved for specific uses

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Schedule explained in detailApproved medicine

Amount status

In the US, lixisenatide is available as a fixed component of the Soliqua 100/33 pen and is titrated once daily in pen units per the combination label. The earlier Lyxumia monotherapy was withdrawn in the EU in 2025 for commercial reasons.

Profile evidence level: established.

Timing

Soliqua within one hour before the first meal; do not derive separate lixisenatide self-dosing from the combination labeling.

No individual recommendation.

Cycle/duration

Approved long-term T2D treatment in the combination pen, no community cycle.

No individual recommendation.

Mixing & calculations

No. The named ready-made solutions are not mixed with water. A research powder is a different product.

All preparation informationProduct details and calculation examples from the available sources.

No reconstitution: Soliqua is a prefilled pen with a fixed insulin glargine/lixisenatide combination. Pen units are not equivalent to a vial's U-100 reconstitution arithmetic.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

GLP-1 receptor agonist

Lixisenatide is classified as “GLP-1 receptor agonist”. Influences post-meal glucose mainly through insulin, glucagon and gastric-emptying signals. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

GLP-1 receptor activation

Researchers study how activating the GLP-1 receptor affects fullness, stomach emptying, and insulin release after a meal. They typically measure blood sugar curves, body weight, and food intake over time, similar to tracking how quickly someone feels hungry again after eating.

02

Blood sugar and appetite outcomes

Researchers study how a substance changes blood sugar levels and feelings of hunger over the course of a day, similar to tracking how full someone feels after different meals. Typical measures include blood glucose readings and questionnaires about hunger and food intake.

03

Gastric emptying

This examines how quickly food leaves the stomach and enters the intestine, a process that influences how full someone feels after eating. Emptying speed is typically measured using imaging or breath tests, similar to timing how long a meal takes to move through the digestive system.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Weight management forums

In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.

General wellness forums

Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

  • Gastrointestinal effects, dehydration, and changes in glucose or appetite may occur depending on the target; incretin medicines can also carry gallbladder, pancreatic and retinopathy warnings.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Pregnancy, severe gastric-emptying disorders, and relevant pancreatic, gallbladder, renal or endocrine disease require professional assessment; the exact label may add contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on substance and indication, weight, blood pressure, hydration, glucose/HbA1c, kidney and liver markers, and concomitant medicines may be reviewed; symptoms guide further tests.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Established

Evidence comes from approval trials; effects on individual people may still vary.

Clinical evidence

The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.

Lixisenatide primarily targets post-meal glucose, differing in emphasis from GLP-1 agents used more like basal coverage.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile